News | July 11, 2023
Sumitomo Pharma America launches as new combined organization
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
Advances clinical research capabilities with leading regulatory grade registries platform
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Collaboration to provide hospitals with a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
Subscribe To Our Newsletter & Stay Updated
